comprehensive -WSS

comprehensive

author：knowledge 2025-10-01 21:35:46 - browse：71

RHONA WISE/AFP via Getty Images

WASHINGTON — Drugmakers are doing everything to tap the bottomless well of demand for new obesity drugs, and they might get some government help. The agency that regulates Obamacare insurance is considering a technical change that would require insurers to cover obesity drugs in a market of more than 20 million Americans.

Weight loss drugs are a blessing for patients, a boon for drugmakers, and a potentially huge expense for insurers and taxpayers. Insurers have been slow to cover the drugs, called GLP-1 agonists, and without insurance, it costs upward of $16,000 annually for a drug that must be taken indefinitely.

There is a lot of demand for the drugs, but there are barriers to coverage. Medicare by law is prohibited from paying for obesity drugs. State Medicaid programs don’t have to cover them, so most don’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： FTC loses bid to block Novant's North Carolina hospital merger

leisure time

WSS

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Medicare Advantage's lean provider networks lead CMS complaints

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Stopping antidepressants leads to symptoms for 1 in 6 patients

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

AstraZeneca to buy developer of next

hotspot

comprehensive

hotspot

Supreme Court strikes down use of affirmative action

The most pressing bird flu mysteries scientists want answered

BioMarin wins approval for gene therapy to treat hemophilia A

Methadone treatment changes are coming. Do they go far enough?

Activists slam private health insurers over coverage restrictions

Structure Therapeutics oral GLP

Medical records are filled with copy

Argenx readies a blockbuster opportunity with drug for autoimmune disease

BioMarin wins approval for gene therapy to treat hemophilia A

A new initiative will help leaders fight the next pandemic

hotspot

UnitedHealth increases loan offers after Change Healthcare outage

How CO2 helps viruses stay alive longer in the air

Sutter Health’s antitrust win overturned by appeals court

BD to buy Edwards patient monitoring unit for $4.2 billion

Colonoscopy prep: Liquid

CMS got Medicare Advantage quality rating wrong, judge rules

entertainment

leisure time

focus

Wikipedia